Results 101 to 110 of about 642,659 (199)

New developments in atherosclerosis: clinical potential of PCSK9 inhibition

, 2015
Ilaria Giunzioni, Hagai Tavori Knight Cardiovascular Institute, Center for Preventive Cardiology, Oregon Health and Science University, Portland, OR, USA Abstract: Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a secreted 692-amino acid ...
Giunzioni I, Tavori H
core  

PCSK9 and Hypercholesterolemia: Therapeutic Approach

, 2018
Despite the intensive research and progress in modern pharmacotherapy, hypercholesterolemia and related cardiovascular complications remain one of the leading causes of mortality and disability in the modern world.
Perović, Milan, Obradović, Milan M., Ilinčić, Branislava, Isenović, Esma R., Branislava Ilincic, Edita Stokic, Stokić, Edita, Zarić, Božidarka, Bozidarka Zaric, Esma R. Isenovic, Milan Perovic, Milan Obradovic, Sudar-Milovanović, Emina, Emina Sudar-Milovanovic   +13 more
core   +1 more source

Targeting PCSK9 in Vascular Smooth Muscle Cells: An Effective Strategy to Suppress Ferroptosis and Attenuate Abdominal Aortic Aneurysm Progression

Cell Proliferation, EarlyView.
PCSK9 aggravates AAA by promoting ferroptosis in VSMCs. In the pathological AAA environment, PCSK9 upregulation triggers ferritinophagy‐dependent degradation of FTH1, leading to Fe2+ release, triggering lipid peroxidation and ferroptosis, exacerbating AAA.
Mengdie Xia, Man Li, Yanyu Chen, Jialin Chen, Yuting Cui, Xi‐Long Zheng, Jing Yang, Bingzhao Li, Xiaofeng Ma, Miao Liu, Gang Fan, Juan Peng, Xiaoyan Dai, Zhihan Tang   +13 more
wiley   +1 more source

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

Journal of Lipid Research, 2010
Over the past several years, proprotein convertase subtilisin kexin type 9 (PCSK9) has gained significant attention as a key regulator of serum LDL-cholesterol (LDL-C) levels.
Jason S. Troutt, William E. Alborn, Guoqing Cao, Robert J. Konrad   +3 more
doaj   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source

PCSK9 promotes progression of anaplastic thyroid cancer through E-cadherin endocytosis

Cell Death and Disease
Although anaplastic thyroid cancer (ATC) constitutes only 1–2% of all thyroid malignancies, it is associated with an exceptionally high mortality rate, accounting for 14–39% of thyroid cancer-related deaths. In this study, we identified the critical role
Yu Zhang, Wei Su, Xiaoyu Ji, Zhou Yang, Qing Guan, Yuanxin Pang, Linkun Zhong, Yu Wang, Jun Xiang   +8 more
doaj   +1 more source

Regulation of PCSK9 During Oxidized LDL-Induced Foam Cell Formation in RAW264.7 Cells

Biology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is traditionally known for regulating plasma LDL cholesterol levels via LDL receptor degradation.
Md Sariful Islam Howlader, Manjusri Das, Surajit Hansda, Md Afjalus Siraj, Hiranmoy Das   +4 more
doaj   +1 more source

Proteomic Pathways Linking Type 2 Diabetes Genetic Clusters to Cardiovascular Diseases: A Network Mendelian Randomisation Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Genetic clusters related to Type 2 diabetes (T2D) have differential impact on cardiovascular diseases (CVDs), although the underlying mechanisms, such as proteomic perturbation, remain unexplored. We conducted a network Mendelian randomisation (MR) study to identify proteomic mediators linking T2D genetic clusters and CVDs.
Shuang Liao, Gabriel Chun Yin Sung, Yiwen Liang, Chenxi Li, Shiu Lun Au Yeung   +4 more
wiley   +1 more source

Are PCSK9 Inhibitors Cost Effective? [PDF]

, 2018
The objective of this study was to review available health economic evaluations of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.
Kristiansen, Ivar Sønbø, Retterstøl, Kjetil, Max J. Korman, Kjetil Retterstøl, Ivar Sønbø Kristiansen, Korman, Max, Wisløff, Torbjørn, Torbjørn Wisløff   +7 more
core   +1 more source

The Mechanisms of PCSK9 Inhibitor Reducing Lipoprotein(a)

Shengwu huaxue yu shengwu wuli jinzhan
Lipoprotein(a) (Lp(a)) is a complex circulating lipoprotein, and increasing evidence has demonstrated its role as a risk factor for atherosclerotic cardiovascular disease and as a possible therapeutic target.
XUE Yu, LIU Hai-Wei, LI Yang
doaj   +1 more source